Abstract
Background
In 2016, the National Comprehensive Cancer Network included neoadjuvant chemotherapy as a treatment option for patients with clinical T4b colon cancer. However, there is little published data on the survival impact of neoadjuvant chemotherapy for locally advanced colon cancer.
Methods
Adult patients with non-metastatic clinically staged T3 or T4 colon cancer who underwent surgical resection were identified from the National Cancer Data Base between 2006 and 2014. Treatment was categorized as neoadjuvant chemotherapy followed by surgery and surgery followed by adjuvant chemotherapy. Overall survival was compared between the two groups using propensity score matching.
Results
Of 27,575 patients that met inclusion criteria, 26,654 (97%) were treated with surgery followed by adjuvant chemotherapy and 921 (3%) received neoadjuvant chemotherapy followed by surgery. After propensity score matching, patients with T4b colon cancer treated with neoadjuvant chemotherapy had a 23% lower risk of death at 3 years compared to patients that had adjuvant chemotherapy (HR 0.77, 95% CI 0.60–0.98; p = 0.04). However, neoadjuvant chemotherapy did not demonstrate a similar significant benefit for patients with T3 and T4a disease.
Conclusions
Patients with clinical T4b colon cancer treated with neoadjuvant chemotherapy may have an improved survival compared to those who receive adjuvant chemotherapy. Further prospective investigation is warranted.
Similar content being viewed by others
References
Z. Zhou, H. S. Nimeiri, and A. B. Benson, “Preoperative chemotherapy for locally advanced resectable colon cancer—a new treatment paradigm in colon cancer?,” Ann. Transl. Med., vol. 1, no. 2, p. 11, 2013.
D. A. Agbamu et al., “Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial,” Lancet Oncol., vol. 13, no. 11, pp. 1152–1160, 2012.
T. André et al., “Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.,” J. Clin. Oncol., vol. 27, no. 19, pp. 3109–16, 2009.
T. Lehnert, M. Methner, A. Pollok, A. Schaible, U. Hinz, and C. Herfarth, “Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients.,” Ann. Surg., vol. 235, no. 2, pp. 217–25, 2002.
R. S. Croner, S. Merkel, T. Papadopoulos, V. Schellerer, W. Hohenberger, and J. Goehl, “Multivisceral resection for colon carcinoma,” Dis. Colon rectum, vol. 52, no. 8, pp. 1381–1386, 2009.
Medical Research Council Oesophageal Cancer Working Party*, “Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.,” Lancet, vol. 359, no. 9319, pp. 1727–33, 2002.
D. Cunningham et al., “Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer,” N Engl J Med, vol. 355, no. 1, pp. 11–20, 2006.
D. Sebag-Montefiore et al., “Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial,” Lancet, vol. 373, no. 9666, pp. 811–820, 2009.
K. Tanaka et al., “Metastatic Tumor Doubling Time: Most Important Prehepatectomy Predictor of Survival and Nonrecurrence of Hepatic Colorectal Cancer Metastasis,” World J. Surg., vol. 28, no. 3, pp. 263–270, 2004.
H. Nelson et al., “Guidelines 2000 for colon and rectal cancer surgery,” J Natl Cancer Inst, vol. 93, no. 8, pp. 583–596, 2001.
P. J. Guillou et al., “Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): Multicentre, randomised controlled trial,” Lancet, vol. 365, no. 9472, pp. 1718–1726, 2005.
A. Jakobsen et al., “Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial.,” Acta Oncol., vol. 54, no. 10, pp. 1747–1753, 2015.
NCCN, “NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer,” Version 1.2017, 2016.
University of Birmingham. Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery. Available at https://clinicaltrials.gov/
F. Lordick et al., “PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial,” Lancet Oncol., vol. 8, no. 9, pp. 797–805, 2007.
L. E. McCahill et al., “Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP Trial C-10,” J. Clin. Oncol., vol. 30, no. 26, pp. 3223–3228, 2012.
N. J. Smith, N. Bees, Y. Barbachano, A. R. Norman, R. I. Swift, and G. Brown, “Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials.,” Br. J. Cancer, vol. 96, no. 7, pp. 1030–6, 2007.
T. Yoh, K. Yamamichi, M. Oishi, R. Iwaki, and T. Motohiro, “[A case of effective neoadjuvant chemoradiotherapy with capecitabine for locally advanced sigmoid colon cancer].,” Gan To Kagaku Ryoho., vol. 38, no. 6, pp. 1021–1024, 2011.
M. Yoshitomi, H. Hashida, A. Nomura, S. Ueda, H. Terajima, and N. Osaki, “[A case of locally advanced sigmoid colon cancer treated with neoadjuvant chemoradiotherapy].,” Gan To Kagaku Ryoho., vol. 41, no. 9, pp. 1175–1178, 2014.
H. Mizukami, Y. Yoshizawa, S. Sasaya, H. Nemoto, K. Maezawa, and Y. Sanada, “[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery],” Gan To Kagaku Ryoho, vol. 34, no. 6, pp. 953–956, 2007.
M. Cukier et al., “Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: A single institution experience,” European Journal of Surgical Oncology, vol. 38, no. 8. pp. 677–682, 2012.
S. Burton et al., “MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: Treatment with radiotherapy and chemotherapy,” Int. J. Radiat. Oncol. Biol. Phys., vol. 65, no. 2, pp. 445–451, 2006.
H. Zhou et al., “A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer,” Chinese J. Cancer Res., vol. 28, no. 6, pp. 598–605, 2016.
F. Liu et al., “CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial,” Chinese J. Cancer Res., vol. 28, no. 6, pp. 589–597, 2016.
M. Karoui et al., “Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial—the PRODIGE 22--ECKINOXE trial.,” BMC Cancer, vol. 15, p. 511, 2015.
Author information
Authors and Affiliations
Contributions
Conception of the work: Ahmed Dehal
Data acquisition: All authors
Data analysis: All authors
Data interpretation: All authors
Manuscript drafting and Final approval: All authors
Corresponding author
Rights and permissions
About this article
Cite this article
Dehal, A., Graff-Baker, A.N., Vuong, B. et al. Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer. J Gastrointest Surg 22, 242–249 (2018). https://doi.org/10.1007/s11605-017-3566-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-017-3566-z